CorVel Corp. (NASDAQ:CRVL – Get Free Report) VP Jennifer Yoss sold 1,999 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $61.02, for a total transaction of $121,978.98. Following the completion of the transaction, the vice president directly owned 2,173 shares in the company, valued at $132,596.46. This trade represents a 47.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
CorVel Trading Up 3.8%
NASDAQ CRVL opened at $61.64 on Friday. CorVel Corp. has a 1-year low of $44.83 and a 1-year high of $113.64. The company has a market capitalization of $3.12 billion, a PE ratio of 28.80 and a beta of 0.98. The firm’s fifty day simple moving average is $56.58 and its 200-day simple moving average is $61.25.
CorVel (NASDAQ:CRVL – Get Free Report) last posted its quarterly earnings results on Tuesday, May 19th. The business services provider reported $0.61 earnings per share for the quarter. The business had revenue of $248.55 million for the quarter. CorVel had a net margin of 11.51% and a return on equity of 29.92%.
Institutional Investors Weigh In On CorVel
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded shares of CorVel from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, CorVel has a consensus rating of “Sell”.
View Our Latest Stock Analysis on CorVel
CorVel Company Profile
CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.
The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).
Further Reading
- Five stocks we like better than CorVel
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.
